Log in

NASDAQ:BDSIBioDelivery Sciences International Stock Price, Forecast & News

$4.81
+0.07 (+1.48 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.75
Now: $4.81
$4.92
50-Day Range
$4.06
MA: $4.60
$5.08
52-Week Range
$2.85
Now: $4.81
$7.21
Volume1.10 million shs
Average Volume838,327 shs
Market Capitalization$480.52 million
P/E RatioN/A
Dividend YieldN/A
Beta0.77
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in opioid tolerant adult patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.
Read More
BioDelivery Sciences International logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.88 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:BDSI
CUSIP09060J10
Phone919-582-9050

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$111.39 million
Cash Flow$0.19 per share
Book Value$0.78 per share

Profitability

Net Income$-15,310,000.00

Miscellaneous

Employees178
Market Cap$480.52 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive BDSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BDSI and its competitors with MarketBeat's FREE daily newsletter.

BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions

How has BioDelivery Sciences International's stock been impacted by COVID-19 (Coronavirus)?

BioDelivery Sciences International's stock was trading at $3.96 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BDSI stock has increased by 21.5% and is now trading at $4.81. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BioDelivery Sciences International?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioDelivery Sciences International.

When is BioDelivery Sciences International's next earnings date?

BioDelivery Sciences International is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for BioDelivery Sciences International.

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) issued its quarterly earnings data on Thursday, May, 7th. The specialty pharmaceutical company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.01 by $0.04. The specialty pharmaceutical company had revenue of $38.28 million for the quarter, compared to analyst estimates of $33.19 million. BioDelivery Sciences International had a positive return on equity of 23.61% and a negative net margin of 5.01%. View BioDelivery Sciences International's earnings history.

What price target have analysts set for BDSI?

8 brokerages have issued 1-year price objectives for BioDelivery Sciences International's stock. Their forecasts range from $8.00 to $9.25. On average, they anticipate BioDelivery Sciences International's share price to reach $8.71 in the next twelve months. This suggests a possible upside of 81.0% from the stock's current price. View analysts' price targets for BioDelivery Sciences International.

Has BioDelivery Sciences International been receiving favorable news coverage?

Media coverage about BDSI stock has trended positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. BioDelivery Sciences International earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutBioDelivery Sciences International.

Who are some of BioDelivery Sciences International's key competitors?

What other stocks do shareholders of BioDelivery Sciences International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Eldorado Gold (EGO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Alibaba Group (BABA), Baidu (BIDU), JD.Com (JD), Crispr Therapeutics (CRSP) and Gilead Sciences (GILD).

Who are BioDelivery Sciences International's key executives?

BioDelivery Sciences International's management team includes the following people:
  • Mr. Herm Cukier, CEO & Director (Age 54, Pay $599.46k)
  • Mr. Scott M. Plesha, Pres & Chief Commercial Officer (Age 55, Pay $410.71k)
  • Ms. Mary Theresa Coelho, CFO & Treasurer (Age 58, Pay $410.7k)
  • Mr. James Vollins J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 51, Pay $340.28k)
  • Dr. Thomas B. Smith FAAFP, M.D., Chief Medical Officer (Age 59, Pay $377.89k)

What is BioDelivery Sciences International's stock symbol?

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

Who are BioDelivery Sciences International's major shareholders?

BioDelivery Sciences International's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.43%), Systematic Financial Management LP (2.39%), Emerald Advisers LLC (2.18%), State Street Corp (1.92%), Emerald Mutual Fund Advisers Trust (1.98%) and Nuveen Asset Management LLC (1.71%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Paolantonio Ernest Robert De, Scott M Plesha and Thomas B Smith. View institutional ownership trends for BioDelivery Sciences International.

Which major investors are selling BioDelivery Sciences International stock?

BDSI stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Deutsche Bank AG, Two Sigma Investments LP, Assenagon Asset Management S.A., BlackRock Inc., Bank of New York Mellon Corp, WINTON GROUP Ltd, and Squarepoint Ops LLC. Company insiders that have sold BioDelivery Sciences International company stock in the last year include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Scott M Plesha, and Thomas B Smith. View insider buying and selling activity for BioDelivery Sciences International.

Which major investors are buying BioDelivery Sciences International stock?

BDSI stock was bought by a variety of institutional investors in the last quarter, including Penn Capital Management Co. Inc., Stonepine Capital Management LLC, AQR Capital Management LLC, Systematic Financial Management LP, Grandeur Peak Global Advisors LLC, DG Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., and Cadence Capital Management LLC. View insider buying and selling activity for BioDelivery Sciences International.

How do I buy shares of BioDelivery Sciences International?

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioDelivery Sciences International's stock price today?

One share of BDSI stock can currently be purchased for approximately $4.81.

How big of a company is BioDelivery Sciences International?

BioDelivery Sciences International has a market capitalization of $480.52 million and generates $111.39 million in revenue each year. The specialty pharmaceutical company earns $-15,310,000.00 in net income (profit) each year or $0.10 on an earnings per share basis. BioDelivery Sciences International employs 178 workers across the globe.

What is BioDelivery Sciences International's official website?

The official website for BioDelivery Sciences International is www.bdsi.com.

How can I contact BioDelivery Sciences International?

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.